Craig Mundie
Angel Investor
Seattle, United States
Craig Mundie is a seed investor in Seattle focused on Life Science and Chemical. Craig J. Mundie is based out of Seattle, Washington, and is the Owner of Mundie & Associates LLC. Craig previously worked at Microsoft as a Chief Research and Strategy Officer. Craig J. Mundie attended the Georgia Institute of Technology.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Craig Mundie invests in
Stages Craig Mundie invests in
Countries Craig Mundie invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 2 (50%)
- Chemical 1 (25%)
- Genetics 1 (25%)
- Therapeutics 1 (25%)
- Biotechnology 1 (25%)
Stage
- Seed 1 (25%)
- Series B 1 (25%)
- Series C 1 (25%)
- Funding Round 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creatingstructures comprising up to seven elements. | $5M / Seed / Jan 27, 2019 | ||
| Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M / Sep 27, 2017 | ||
| Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $13.6M / Series C / Jun 17, 2014 | ||
| Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $5.4M / Series B / Dec 21, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Craig Mundie invest in?
Craig Mundie invests primarily in Life Science, Chemical and Genetics startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Craig Mundie?
Public channels for Craig Mundie include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Craig Mundie last invest?
The most recent investment recorded for Craig Mundie closed in Jan 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
